S0820, Adenoma and Second Primary Prevention Trial

Major Program
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
SWOG Cancer Research Network
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01349881
The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Intervention
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
Condition
Colorectal Neoplasms
Investigators
Jason A. Zell, D.O., MPH, David M. King, John A. Ellerton, Deborah W. Wilbur, Amitpal S. Johal, Michal G. Rose, Matthew L. Ryan, Jay W. Carlson, Chung-Tsen Hsueh, Bret E. Friday, James E. Radford, Sukeshi P. Arora, Shailja Roy, Donald J. Jurgens, David A. Mullins, Burke J. Brooks, Donald B. Wender, Arvinder S. Bir, Gamini S. Soori, Bryan A. Faller, Mark F. Kozloff, Mitchell Haut, Richard L. Deming, Uzair B. Chaudhary, Ari D. Baron, Chady A. Leon, Akm Mosharraf Hossain, Harish G. Ahuja, Isoken Koko, Jason A. Zell, Bernard M. Evers, Nina Beri, Nagesh H. Jayaram, Mustapha A. Khalife, Ryan T. Oleszewski, Vincent P. Vinciguerra, Lisa Bailey, Mark E. Reeves, Steven R. Schuster, Aqeel A. Gillani, Timothy D. Moore, Powel H. Brown, Bruce S. Lin, Carroll D. Scroggin, Gary L. Buchschacher, Samantha A. Seaward, Syma Iqbal, Sajid A. Khan, Ahmad Shaker, Olumide B. Gbolahan, Andrew W. Pippas, Stephen White, Kendrith M. Rowland, Muhammad O. Toor, William P. Fusselman, Joshua Lukenbill, Raed Al-Rajabi, Ashkan Bahrani, Tareq Al Baghdadi, Elie B. Choufani, Adarsh Vennepureddy, Gina G. Chung, Albert S. DeNittis, Gene B. Saylors

See list of participating sites